
Finland · Medical devices startup
MVision AI is a health-tech company based in Helsinki, Finland, founded in 2017.
Funding reportedLast round: Seed
Follow MVision AI and see its new rounds in your feed.Start following
MVision AI is a health-tech company based in Helsinki, Finland, founded in 2017.
The company focuses on developing AI-powered, cloud-based software solutions that enhance radiotherapy treatment planning. Its mission is to empower radiation oncology professionals by automating repetitive tasks, standardizing clinical processes, and improving treatment quality for better patient care. The company offers a range of services, including AI-powered automatic segmentation, workflow automation, and a secure cloud-based treatment planning platform. Its flagship products, such as Contour+ and Workspace+, utilize deep learning and computer vision to streamline radiotherapy workflows, significantly reducing manual work and ensuring consistent, high-quality results. MVision AI has treated over 100,000 cancer patients across 14 countries, demonstrating its strong presence in the healthcare sector. The company is committed to innovation and collaboration, aiming to provide personalized cancer treatment while maintaining the highest standards of quality and patient-centricity.
Funding, as reported
From MVision AI's own website: 2 founders, 6 on the team.
What they build
Known for
health caredeep learning segmentationdata protectionclinical workflow efficiencytreatment planninglymph node contouringdistributionbusiness innovationsai contouringmedical equipment manufacturingeducationauto segmentationinformation technology & servicesradiation oncologyguideline-based contouringai-powered radiotherapy solutions
Built with from their website
DockerGoogle Tag ManagerLiteSpeedWordPress.orgGoogle CloudDataTablesFont AwesomeYouTubeGoogle WorkspaceViewport Meta
Google DriveHubspot.NETGoogle Cloud HostingAIGoogle MeetComplianzOWL Carousel
Add your raise, your deck and your story, and put MVision AI in front of investors. Or tell us what we have wrong.